Bender Robert & Associates Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Bender Robert & Associates purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,710 shares of the biotechnology company’s stock, valued at approximately $178,000.

Other institutional investors have also recently bought and sold shares of the company. Venturi Wealth Management LLC acquired a new position in BioCryst Pharmaceuticals during the fourth quarter worth approximately $46,000. R Squared Ltd acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $48,000. KBC Group NV grew its position in shares of BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 4,537 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $80,000. Finally, Quantinno Capital Management LP acquired a new position in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $82,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $7.54 on Wednesday. The business has a fifty day moving average price of $8.15 and a two-hundred day moving average price of $7.87. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.50. The stock has a market capitalization of $1.58 billion, a PE ratio of -12.36 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. During the same period in the previous year, the firm earned $0.28 EPS. BioCryst Pharmaceuticals’s revenue was up 40.8% on a year-over-year basis. As a group, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

BCRX has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price on the stock. Evercore ISI upped their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.